View Item 

Show simple item record

In vivo biodistribution of 125IPIP and internal dosimetry of 123IPIP radioiodinated agents selective to the muscarinic acetylcholinergic receptor complex
dc.contributor.authorBreeden, William K.
dc.contributor.authorHamby, David M.
dc.contributor.authorCarey, James E.
dc.contributor.authorEckerman, Keith F.
dc.contributor.authorMcPherson, Daniel W.
dc.contributor.authorKnapp, Furn F.
dc.date.accessioned2017-01-06T20:48:16Z
dc.date.available2017-01-06T20:48:16Z
dc.date.issued2000-04
dc.identifier.citationBreeden, William K.; Hamby, David M.; Carey, James E.; Eckerman, Keith F.; McPherson, Daniel W.; Knapp, Furn F. (2000). "In vivo biodistribution of 125IPIP and internal dosimetry of 123IPIP radioiodinated agents selective to the muscarinic acetylcholinergic receptor complex." Medical Physics 27(4): 778-786.
dc.identifier.issn0094-2405
dc.identifier.issn2473-4209
dc.identifier.urihttps://hdl.handle.net/2027.42/134943
dc.publisherWiley Periodicals, Inc.
dc.publisherAmerican Association of Physicists in Medicine
dc.subject.otherBrain
dc.subject.otherbiodistribution
dc.subject.otheriodine
dc.subject.otherinternal dosimetry
dc.subject.othermuscarinic acetylcholinergic complex
dc.subject.otherradiopharmaceuticals
dc.subject.otherbiokinetics
dc.subject.otherrat studies
dc.subject.otherSingle photon emission computed tomography (SPECT)
dc.subject.otherdosimetry
dc.subject.othercardiology
dc.subject.otherbrain
dc.subject.othersingle photon emission computed tomography
dc.subject.otherradioactive tracers
dc.subject.othertumours
dc.subject.otherAnatomy
dc.subject.otherHeart
dc.subject.otherRadiopharmaceuticals
dc.subject.otherMedical imaging
dc.subject.otherSingle photon emission computed tomography
dc.subject.otherCancer
dc.subject.otherCardiac dynamics
dc.subject.otherDosimetry
dc.subject.otherTherapeutics
dc.titleIn vivo biodistribution of 125IPIP and internal dosimetry of 123IPIP radioiodinated agents selective to the muscarinic acetylcholinergic receptor complex
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMedicine (General)
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumDepartment of Nuclear Medicine, University of Michigan, Ann Arbor, Michigan 48109‐0028
dc.contributor.affiliationumDepartment of Environmental and Industrial Health, School of Public Health, University of Michigan, Ann Arbor, Michigan 48109‐2029
dc.contributor.affiliationotherOak Ridge National Laboratory, 1060 Commerce Park, Oak Ridge, Tennessee 37831‐6480
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/134943/1/mp8941.pdf
dc.identifier.doi10.1118/1.598941
dc.identifier.sourceMedical Physics
dc.identifier.citedreferenceInternational Commission On Radiological Protection (ICRP), Limits for Intakes of Radionuclides by Workers (Oxford Pergamon Press, New York, 1979), ICRP Publication No. 30. Annals of ICRP 2 No. 3/4.
dc.identifier.citedreferenceD. W. McPherson et al., “ Resolution and in vitro and initial in vivo of isomers of iodine‐125‐labled 1‐azabicyclo[2.2.2]oct‐3‐yl α‐hydroxy‐α‐(1‐iodo‐1‐propen‐3‐yl)‐α‐phenylacetate: A high‐affinity ligand for the muscarinic receptor,” J. Med. Chem. JMCMAR --> 38, 3909 – 3911 ( 1995 ).
dc.identifier.citedreferenceR. E. Remington, I. W. Remington, and S. S. Welsch, “ The thyroid gland of the normal rat: V, dry matter and iodine content,” Anat. Rec. ANREAK --> 67, 367 ( 1937 ).
dc.identifier.citedreferenceM. R. Rayeq, S. F. Boulay, V. K. Sood, D. W. McPherson, F. F. Knapp, Jr., and B. R. Zeeberg, “ In vivo autoradiographic and dissection evaluation of isomers of 125 I labeled 1‐azabicyclo [2.2.2]oct‐3‐yl‐α‐(1‐iodo‐1‐propen‐3‐yl)‐α‐phenylacetate (IQNP),” Receptors and Signal Transduction 6, 13 – 34 ( 1996 ).
dc.identifier.citedreferenceUniversity of Washington, SAAMII Program. Seattle, Washington; 1997.
dc.identifier.citedreferenceR. W. Leggett, K. F. Eckerman, and L. R. Williams, “ ACTACAL/ACTLITE numerical method: An elementary method for implementing complex biokinetic models,” Health Phys. HLTPAO --> 64, 260 – 278 ( 1993 ).
dc.identifier.citedreferenceW. Walker, J. R. Parrington, and F. Feiner, Nuclides and Isotopes, Fourteenth Edition (GE Nuclear Company, 1989).
dc.identifier.citedreferenceR. Loevinger, T. F. Budinger, and E. E. Watson, MIRD primer for absorbed dose calculations (The Society of Nuclear Medicine, New York, 1991).
dc.identifier.citedreferenceInternational Commission On Radiological Protection (CRP), Report of the Task Group on Reference Man (Oxford Pergamon Press, New York, 1975), ICRP Publication No. 23. pp. 13–219.
dc.identifier.citedreferenceM. Cristy and K. F. Eckerman, “SEECAL: Program to calculate age‐dependent specific effective energies,” Oak Ridge National Laboratory. Martin Marietta Energy Systems, Inc. Oak Ridge, TN: US Department of Energy. Report No. TM‐12351; 1993.
dc.identifier.citedreferenceD. A. Weber, K. F. Eckerman, L. T. Dillman, and J. C. Ryman, MIRD Radionuclide Data and Decay Schemes (Society of Nuclear Medicine, New York, 1989).
dc.identifier.citedreferenceM. Cristy and K. F. Eckerman, “Specific absorbed fractions of energy at various ages from internal photon sources,” Oak Ridge National Laboratory. Martin Marietta Energy Systems, Inc. Oak Ridge, TN: US Department of Energy. Report No. ORNL/TM‐8381/V1‐V7; 1987.
dc.identifier.citedreferenceR. Frankel and K. Bergene, “The FDA’s requirements for radiation dosimetry of radiopharmaceutical drug products,” Fourth International Radiopharmaceutical Dosimetry Symposium Proceedings. Oak Ridge Associated Universities. Oak Ridge, TN: Report No. 851113. pp. 267–273; 1985.
dc.identifier.citedreferenceCommission On Radiological Protection (ICRP), Age‐Dependent Doses to Members of the Public from Intake of Radionuclides: Part 2 Ingestion Dose Coefficients (Oxford Pergamon Press, New York, 1993), ICRP Publication No. 67. Annals of ICRP 23 No. 3/4.
dc.identifier.citedreferenceH. D. Roedler, “Accuracy of internal dose calculations with special consideration of radiopharmaceutical biokinetics,” Third Radiopharmaceutical Dosimetry Symposium Proceedings. Oak Ridge National Laboratory. Oak Ridge, TN: HHS‐Publ (FDA) 81‐8166: 6‐7; 1980.
dc.identifier.citedreferenceM. McKinney and J. Coyle, “ The potential for muscarinic receptor subtype‐specific pharmacotherapy for Alzheimer’s disease,” Mayo Clin. Proc. MACPAJ --> 66, 1226 – 1230 ( 1991 ).
dc.identifier.citedreferenceD. W. McPherson, D. L. DeHaven‐Hudkins, A. P. Callahan, and F. F. Knapp, Jr., “ Synthesis and biodistribution of iodine‐125‐labeled 1‐azabicyclo[2.2.2]oct‐3‐yl α‐hydroxy‐α‐(1‐iodo‐1‐propen‐3‐yl)‐α‐phenylacetate: A new liganed for the potential imaging of muscarinic receptors by single photon emission computed tomography,” J. Med. Chem. JMCMAR --> 36, 848 – 854 ( 1993 ).
dc.identifier.citedreferenceE. Hellstrom‐Lindahl, B. Winblad, and A. Nordberg, “ Muscarinic and nicotinic receptor changes in the cortex and thalamus of brains of chronic alcoholics,” Brain Res. BRREAP --> 620, 42 – 48 ( 1993 ).
dc.identifier.citedreferenceD. M. Araujo, P. A. Lapchak, and R. Quirion, “ Heterogeneous binding of [3H] 4‐DAMP tp muscarinic cholingergic sites in the rat brain: Evidence from membrane binding and autoradiographic studies,” Synapse 9, 165 – 176 ( 1991 ).
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
mp8941.pdf
Size:
86.39KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.